IISc and DTU report a five-nanobody antivenom that covers Indian cobras and king cobras

Researchers at the Indian Institute of Science and the Technical University of Denmark have published a recombinant antivenom built from five nanobodies that, in mice, stopped venom from India's spectacled cobra, monocled cobra and both king cobra species. The paper, "Oligoclonal nanobody-based recombinant antivenom protects mice challenged with venom from cobras and king cobras from India," appeared in Science Translational Medicine on 9 September.

Snakebite still kills more than 100,000 people a year worldwide. India accounts for close to half of that total, a burden often put above 50,000 deaths. The standard treatment is equine plasma antivenom raised in horses. Those products vary by batch, can trigger severe reactions, and lose force when the snake and the horse were not from the same region. India's common polyvalent antivenom is raised mainly on venom collected around Chennai. It is aimed at the "big four" (spectacled cobra, common krait, Russell's viper, saw-scaled viper). It does not cover king cobra. A production line for king cobra antivenom in Assam was shut because demand was low.

The new cocktail is a different object. Andreas Hougaard Laustsen's group in Denmark had already pulled camelid antibody fragments, nanobodies, from animals immunised with African elapid venoms and grown those fragments in microbial cells. Kartik Sunagar's group at IISc's Centre for Ecological Sciences then chose five of those fragments that bind the toxin families that matter in Indian cobras: alpha-neurotoxins, cytotoxins and phospholipases A2. Because the fragments are grown in the lab, the process does not need a fresh horse or camel for every batch.

In preincubation tests and in rescue tests, the five-nanobody mix protected mice against Naja naja from sites across India, Naja kaouthia, Ophiophagus kaalinga from the Western Ghats and Ophiophagus hannah from the Northeast. Mice lived even when the cocktail was given 30 minutes after the venom. That last point matters in a country where the interval between bite and hospital door is often longer than 30 minutes.

Sunagar said antivenom treatment has barely moved in a hundred years and called this the first next-generation product aimed at India's cobra problem. That claim is about method, not about a medicine on a shelf. The work is still in animals. Dose, stability, cost, cold chain and human safety have not been settled. A recombinant product that covers king cobra would fill a gap that the Chennai polyvalent does not touch. It would not, by itself, cut the 50,000-death tally, which is driven as much by viper bites, late arrival and missing stock as by cobra neurotoxins.

Venom chemistry changes with geography. An antivenom raised on northern snakes can fail in Kerala. The IISc-DTU paper tries to solve that for cobras by picking toxin families that recur across sites rather than a single local venom. The same approach will have to be repeated for vipers if the method is to become a national protocol. Eight viper species in Kerala still have no specific antivenom.

What the paper adds is a measured object: five named fragments, four named species, two test designs, a 30-minute rescue window in mice. Hospitals cannot order it. Regulators have not seen a human dossier. For a disease that kills tens of thousands of Indians a year with a 19th-century manufacturing model, that is still a change in the file.